|
|
|
Insider
Information: |
Baker Felix |
Relationship: |
Director, 10% Owner |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
20 |
|
Direct
Shares |
927,207 |
|
Indirect Shares
|
141,861,898 |
|
|
Direct
Value |
$81,596,522 |
|
|
Indirect Value
|
$12,923,651,413 |
|
|
Total
Shares |
142,789,105 |
|
|
Total
Value |
$13,005,247,936 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
36
|
6
|
Stock
price went up :
|
15
|
6
|
Stock
price went down : |
21
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
6.0
|
Percentage
Gain/Loss : |
-24.3%
|
18.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Incyte Corp |
INCY |
Director, 10% Owner |
2023-09-29 |
559,963 |
2023-09-29 |
33,480,292 |
Premium* |
|
Ardea Biosciences Inc |
RDEA |
Director, 10% Owner |
2003-10-06 |
0 |
2012-02-01 |
116,454 |
Premium* |
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2018-02-01 |
215,015 |
2018-02-01 |
44,355,335 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
Director, 10% Owner |
2015-06-22 |
100,503 |
2015-06-22 |
9,328,233 |
Premium* |
|
Viropharma Inc |
VPHM |
10% Owner |
2005-01-31 |
0 |
2011-12-14 |
303,264 |
Premium* |
|
Aceragen, Inc |
ACGN |
Director |
|
0 |
2017-07-03 |
145,453 |
Premium* |
|
Tapestry Pharmaceuticals Inc |
TPPHQ |
10% Owner |
|
0 |
2008-10-15 |
0 |
Premium* |
|
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2012-10-01 |
288 |
2012-10-01 |
11,377,485 |
Premium* |
|
Allos Therapeutics Inc |
ALTH |
10% Owner |
|
0 |
2009-02-06 |
1,629 |
Premium* |
|
Biocryst Pharmaceuticals Inc |
BCRX |
10% Owner |
2016-08-16 |
46,918 |
2016-08-16 |
9,418,390 |
Premium* |
|
Heron Therapeutics Inc |
HRTX |
10% Owner |
|
0 |
2011-06-30 |
5,266,568 |
Premium* |
|
Adolor Corp |
ADLR |
10% Owner |
2010-04-26 |
0 |
2011-12-19 |
0 |
Premium* |
|
Diadexus Inc |
DDXS |
10% Owner |
|
0 |
2010-07-28 |
140,525 |
Premium* |
|
Pharmacyclics Inc |
PCYC |
10% Owner |
|
0 |
2011-08-22 |
1,809 |
Premium* |
|
Ocera Therapeutics Inc |
OCRX |
10% Owner |
2012-03-12 |
0 |
2012-03-14 |
57,704 |
Premium* |
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2012-10-29 |
0 |
2012-10-29 |
480,639 |
Premium* |
|
Neurogene |
NGNE |
10% Owner |
2015-08-07 |
4,520 |
|
0 |
Premium* |
|
Invitae Corp |
NVTA |
10% Owner |
|
0 |
2015-08-27 |
6,554,967 |
Premium* |
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
|
0 |
2015-12-24 |
4,865,647 |
Premium* |
|
Kodiak Sciences Inc. |
KOD |
Director, 10% Owner |
2022-01-21 |
0 |
2022-06-06 |
15,967,504 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
1397 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 53 of 56
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
VPHM |
Viropharma Inc |
10% Owner |
|
2006-02-28 |
4 |
S |
$19.90 |
$2,465,505 |
I/I |
(122,854) |
2,150,377 |
|
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2012-05-08 |
4 |
B |
$28.41 |
$2,480,619 |
I/I |
86,033 |
232,464 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2011-08-23 |
4 |
B |
$14.60 |
$2,528,388 |
I/I |
171,009 |
13,652,467 |
2.25 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2008-06-27 |
4 |
S |
$15.41 |
$2,556,118 |
I/I |
(165,874) |
300,892 |
0 |
- |
|
VPHM |
Viropharma Inc |
10% Owner |
|
2007-11-08 |
4 |
B |
$7.43 |
$2,593,849 |
I/I |
348,917 |
4,580,098 |
1.5 |
- |
|
INCY |
Incyte Corp |
10% Owner |
|
2003-09-19 |
4 |
B |
$5.04 |
$2,649,672 |
I/I |
526,000 |
1,412,855 |
1.5 |
- |
|
INCY |
Incyte Corp |
Director |
|
2010-09-23 |
4 |
S |
$14.86 |
$2,669,654 |
I/I |
(179,644) |
7,511,046 |
0 |
- |
|
VPHM |
Viropharma Inc |
10% Owner |
|
2006-02-27 |
4 |
S |
$21.58 |
$2,692,747 |
I/I |
(123,987) |
2,273,231 |
|
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2012-03-02 |
4 |
B |
$29.52 |
$2,699,915 |
I/I |
91,459 |
8,058,823 |
2.25 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2004-05-05 |
4 |
B |
$13.00 |
$2,724,904 |
I/I |
209,608 |
405,239 |
1.5 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2011-12-02 |
4 |
B |
$28.03 |
$2,729,234 |
I/I |
97,295 |
6,881,247 |
2.25 |
- |
|
KOD |
Kodiak Sciences Inc. |
Director |
|
2022-01-28 |
4 |
B |
$49.70 |
$2,786,084 |
I/I |
55,258 |
14,336,671 |
2.25 |
% |
|
GHDX |
Genomic Health Inc |
Director |
|
2011-11-11 |
4 |
B |
$27.66 |
$2,789,006 |
I/I |
100,823 |
6,486,499 |
2.25 |
- |
|
INCY |
Incyte Corp |
10% Owner |
|
2003-09-19 |
4 |
B |
$5.04 |
$2,802,557 |
I/I |
556,350 |
1,020,307 |
1.5 |
- |
|
INCY |
Incyte Corp |
Director |
|
2008-01-04 |
4 |
B |
$9.47 |
$2,828,166 |
I/I |
298,752 |
4,575,438 |
2.25 |
- |
|
GHDX |
Genomic Health Inc |
N/A |
|
2006-09-08 |
4 |
B |
$14.12 |
$2,832,727 |
I/I |
199,911 |
713,044 |
0.01 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2004-05-05 |
4 |
B |
$13.00 |
$2,885,948 |
I/I |
221,996 |
430,901 |
1.5 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2009-08-11 |
4 |
B |
$10.75 |
$2,939,093 |
I/I |
273,404 |
4,626,213 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-12-08 |
4 |
B |
$13.44 |
$2,992,186 |
I/I |
222,320 |
11,706,343 |
2.25 |
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2009-02-05 |
4 |
S |
$8.11 |
$3,031,791 |
I/I |
(372,365) |
6,524,165 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2007-03-09 |
4 |
B |
$18.28 |
$3,081,430 |
I/I |
168,560 |
1,738,099 |
2.25 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2008-06-06 |
4 |
B |
$20.01 |
$3,212,600 |
I/I |
159,010 |
3,427,082 |
2.25 |
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2009-02-04 |
4 |
S |
$8.01 |
$3,235,233 |
I/I |
(387,589) |
2,416,303 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2010-09-22 |
4 |
S |
$14.71 |
$3,340,623 |
I/I |
(227,071) |
7,690,690 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2011-11-07 |
4 |
B |
$26.20 |
$3,474,033 |
I/I |
132,371 |
6,276,241 |
2.25 |
- |
|
1397 Records found
|
|
Page 53 of 56 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|